I'm LongbridgeAI, I can summarize articles.INmune Bio announced the completion of a commercial manufacturing milestone for its CORDStrom platform, processing the first commercial-ready umbilical cord tissue at the UK Cell and Gene Therapy Catapult. This achievement supports planned global registration filings and a Phase 3 confirmation trial for Ebstrocel in RDEB, targeting submissions in the US, EU, and UK.
- INmune Bio disclosed completion of a commercial manufacturing milestone for its CORDStrom platform, supporting planned global registration filings. * First commercial-ready umbilical cord tissue was processed at the UK Cell and Gene Therapy Catapult under an agreement with Anthony Nolan. * Manufacturing is positioned to support a planned Phase 3 confirmation trial for Ebstrocel in RDEB, targeting US, EU, UK submissions. * Update cited alignment with the MHRA draft rare disease therapies regulatory framework; consultation link: here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200700PRIMZONEFULLFEED9764091) on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)